Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

Metabolic syndrome with the atypical antipsychotics

(2011) Pornpoj Pramyothin et al.   Current Opinion in Endocrinology Diabetes and Obesity

D2Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis

(2010) Jian-Ping Zhang et al.   AMERICAN JOURNAL OF PSYCHIATRY

Lack of association between the −759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients

(2010) Y.-M. Park et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics

(2010) Fabiana B. Kohlrausch et al.   Pharmacogenetics and Genomics

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment

(2010) Chen-Jee Hong et al.   Pharmacogenetics and Genomics

Association ofHTR2C, but notLEPorINSIG2, genes with antipsychotic-induced weight gain in a German sample

(2010) Carolin Opgen-Rhein et al.   PHARMACOGENOMICS

Absence of weight gain association with the HTR2C −759C/T polymorphism in patients with schizophrenia treated with iloperidone

(2010) Andrew Thompson et al.   PSYCHIATRY RESEARCH

Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders

(2009)   AMERICAN JOURNAL OF PSYCHIATRY

Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects

(2009) Karolina Åberg et al.   BIOLOGICAL PSYCHIATRY

Tardive dyskinesia and new antipsychotics

(2009) Christoph U Correll et al.   CURRENT OPINION IN PSYCHIATRY

Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia

(2009) Clement C. Zai et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Multiple Genetic Factors in Olanzapine-Induced Weight Gain in Schizophrenia Patients

(2009) Hiroshi Ujike et al.   JOURNAL OF CLINICAL PSYCHIATRY

Applicability of a Genetic Signature for Enhanced Iloperidone Efficacy in the Treatment of Schizophrenia

(2009) Simona Volpi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine

(2009) Arzu Gunes et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Schizophrenia

(2009) Jim van Os et al.   LANCET

Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta-analysis

(2009) Diederik E. Tenback et al.   MOVEMENT DISORDERS

CYP2D6 Genotype Predicts Antipsychotic Side Effects in Schizophrenia Inpatients: A Retrospective Matched Case-Control Study

(2009) Camilla J. Kobylecki et al.   NEUROPSYCHOBIOLOGY

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

(2009) B Laika et al.   PHARMACOGENOMICS JOURNAL

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

(2009) R Hwang et al.   PHARMACOGENOMICS JOURNAL

Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene

(2009) B R Godlewska et al.   PHARMACOGENOMICS JOURNAL

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia

(2009) A.F.Y. Al Hadithy et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

(2009) Shih-Fen Chen et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes

(2009) Clement C. Zai et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

G-protein β3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients

(2009) Young-Min Park et al.   Psychiatry Investigation

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

(2009) Ana Alkelai et al.   PSYCHOPHARMACOLOGY

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

(2009) Shih-Fen Chen et al.   PSYCHOPHARMACOLOGY

Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients

(2008) I. Omer Barlas et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Meta-Analysis of the Cognitive Effects of the Catechol-O-Methyltransferase Gene Val158/108Met Polymorphism

(2008) Jennifer H. Barnett et al.   BIOLOGICAL PSYCHIATRY

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics

(2008) Dalila Benmessaoud et al.   BMC Psychiatry

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

(2008) Anna Crescenti et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

(2008) J. McGrath et al.   EPIDEMIOLOGIC REVIEWS

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

(2008) Jun Soo Kwon et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients

(2008) Yu-Chih Shen et al.   JOURNAL OF PSYCHIATRIC RESEARCH

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment

(2008) B Wilffert et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

(2008) René S Kahn et al.   LANCET

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

(2008) P R Bakker et al.   MOLECULAR PSYCHIATRY

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

(2008) M Kato et al.   MOLECULAR PSYCHIATRY

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

(2008) C Lavedan et al.   MOLECULAR PSYCHIATRY

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

(2008) S Volpi et al.   MOLECULAR PSYCHIATRY

Val158Met Polymorphism in the Catechol-O-Methyltransferase (COMT) Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia

(2008) Seung-Gul Kang et al.   NEUROPSYCHOBIOLOGY

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

(2008) Masashi Ikeda et al.   PHARMACOGENOMICS

Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis

(2008) Renan P. Souza et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes

(2008) Vita Dolžan et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients

(2008) Martina Rojnic Kuzman et al.   PSYCHIATRY RESEARCH